inclusion criteria: 1. able to understand and provide informed consent 2. individual ≥ 18 years of age. 3. recipient of kidney transplant \>=12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment 4. maintenance immunosuppressive regimen consisting of cni and mycophenolate mofetil or mycophenolate, with or without \<= 5mg/day prednisone or equivalent 5. received completed primary series (3 doses) of mrna vaccine (either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine) as specified in the respective package inserts 6. receipt a covid-19 bivalent mrna booster (moderna or pfizer-biontech) \>30 days prior to enrollment. 7. serum antibody titer up to 2500 u/ml at \>=30 days from the last dose of mrna covid-19 vaccine and =\>30 days following receipt of a monoclonal antibody product or convalescent plasma for covid-19, measured using the roche elecsys(r) anti-sars-cov-2 s assay 8. platelet count greater than 30,000/cu mm must be confirmed in participants with a known history of bleeding disorder or thrombocytopenia (platelet count \<50,000/cu mm) 9. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: 1. is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile or 2. is of childbearing potential and agrees to use an effective contraceptive method or abstinence for 12 weeks post vaccine and while taking mycophenolate mofetil/mycophenolic acid

inclusion criteria: 1. able to understand and provide informed consent 2. individual ≥ 18 years of age. 3. recipient of kidney transplant \>=12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment 4. maintenance immunosuppressive regimen consisting of cni and mycophenolate mofetil or mycophenolate, with or without \<= 5mg/day prednisone or equivalent 5. received completed primary series (3 doses) of mrna vaccine (either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine) as specified in the respective package inserts 6. receipt a covid-19 bivalent mrna booster (moderna or pfizer-biontech) \>30 days prior to enrollment. 7. serum antibody titer up to 2500 u/ml at \>=30 days from the last dose of mrna covid-19 vaccine and =\>30 days following receipt of a monoclonal antibody product or convalescent plasma for covid-19, measured using the roche elecsys(r) anti-sars-cov-2 s assay 8. platelet count greater than 30,000/cu mm must be confirmed in participants with a known history of bleeding disorder or thrombocytopenia (platelet count \<50,000/cu mm) 9. a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: 1. is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile or 2. is of childbearing potential and agrees to use an effective contraceptive method or abstinence for 12 weeks post vaccine and while taking mycophenolate mofetil/mycophenolic acid

inclusion criteria: able to understand and provide informed consent individual ≥ 18 years of age. recipient of kidney transplant >=12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment maintenance immunosuppressive regimen consisting of cni and mycophenolate mofetil or mycophenolate, with or without <= 5mg/day prednisone or equivalent received completed primary series (3 doses) of mrna vaccine (either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine) as specified in the respective package inserts receipt a covid-19 bivalent mrna booster (moderna or pfizer-biontech) >30 days prior to enrollment. serum antibody titer up to 2500 u/ml at >=30 days from the last dose of mrna covid-19 vaccine and =>30 days following receipt of a monoclonal antibody product or convalescent plasma for covid-19, measured using the roche elecsys(r) anti-sars-cov-2 s assay platelet count greater than 30,000/cu mm must be confirmed in participants with a known history of bleeding disorder or thrombocytopenia (platelet count <50,000/cu mm) a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile or is of childbearing potential and agrees to use an effective contraceptive method or abstinence for 12 weeks post vaccine and while taking mycophenolate mofetil/mycophenolic acid

inclusion criteria: able to understand and provide informed consent individual ≥ 18 years of age. recipient of kidney transplant >=12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment maintenance immunosuppressive regimen consisting of cni and mycophenolate mofetil or mycophenolate, with or without <= 5mg/day prednisone or equivalent received completed primary series (3 doses) of mrna vaccine (either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine) as specified in the respective package inserts receipt a covid-19 bivalent mrna booster (moderna or pfizer-biontech) >30 days prior to enrollment. serum antibody titer up to 2500 u/ml at >=30 days from the last dose of mrna covid-19 vaccine and =>30 days following receipt of a monoclonal antibody product or convalescent plasma for covid-19, measured using the roche elecsys(r) anti-sars-cov-2 s assay platelet count greater than 30,000/cu mm must be confirmed in participants with a known history of bleeding disorder or thrombocytopenia (platelet count <50,000/cu mm) a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile or is of childbearing potential and agrees to use an effective contraceptive method or abstinence for 12 weeks post vaccine and while taking mycophenolate mofetil/mycophenolic acid

inclusion criteria: able to understand and provide informed consent recipient of kidney transplant >=12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment maintenance immunosuppressive regimen consisting of cni and mycophenolate mofetil or mycophenolate, with or without <= 5mg/day prednisone or equivalent received a minimum of 2 doses mrna vaccine (either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine) as specified in the respective package inserts with the most recent dose given >30 days before enrollment serum antibody titer up to 2500 u/ml at >=30 days from the last dose of mrna covid-19 vaccine and =>30 days following receipt of a monoclonal antibody product or convalescent plasma for covid-19, measured using the roche elecsys(r) anti-sars-cov-2 s assay platelet count greater than 30,000 must be confirmed in participants with a known history of bleeding disorder or thrombocytopenia (platelet count <50,000 add units) a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile or is of childbearing potential and agrees to use an effective contraceptive method or abstinence for 12 weeks post vaccine and while taking mycophenolate mofetil/mycophenolic acid

inclusion criteria: able to understand and provide informed consent recipient of kidney transplant >=12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment maintenance immunosuppressive regimen consisting of cni and mycophenolate mofetil or mycophenolate, with or without <= 5mg/day prednisone or equivalent received a minimum of 2 doses mrna vaccine (either the moderna covid-19 vaccine or pfizer-biontech covid-19 vaccine) as specified in the respective package inserts with the most recent dose given >30 days before enrollment serum antibody titer up to 2500 u/ml at >=30 days from the last dose of mrna covid-19 vaccine and =>30 days following receipt of a monoclonal antibody product or convalescent plasma for covid-19, measured using the roche elecsys(r) anti-sars-cov-2 s assay platelet count greater than 30,000 must be confirmed in participants with a known history of bleeding disorder or thrombocytopenia (platelet count <50,000 add units) a female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: is of non-childbearing potential. to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year or surgically sterile or is of childbearing potential and agrees to use an effective contraceptive method or abstinence for 12 weeks post vaccine and while taking mycophenolate mofetil/mycophenolic acid